Aromatase inhibitors work by blocking estrogen production and are effective breast cancer treatments in estrogen receptor-positive breast cancer; however, by dramatically reducing estrogen levels, they increase the rate of bone loss and fracture risk [23]. Here, CYP19A1 is linked to breast carcinoma.